Silence Therapeutics plc (SLN) P/B ratio

P/B ratio today
15.0×

Silence Therapeutics plc (SLN) trades at 15.0× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 4.6×. That is 94.1% higher than the 2.4× of fiscal 2024. Figures as of 18 Nov 2026, 13:09 UTC, from Yahoo Finance.

Key facts

P/B ratio today
15.0×
P/B ratio, fiscal 2025
4.6×
Change on fiscal 2024
+94.1%
Highest on record
29.3×fiscal 2023
Lowest on record
2.4×fiscal 2024
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Silence Therapeutics plc P/B ratio, in more detail

Today's figure is 225.7% above the fiscal 2025 year-end.

Across the 4 fiscal year-ends on record (2022–2025), the highest was 29.3× in fiscal 2023 and the lowest 2.4× in fiscal 2024. Today's P/B ratio is higher than at 50% of the 4 fiscal year-ends on record; their median is 11.5×.

History · 4 fiscal years

P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Silence Therapeutics plc P/B ratio, year by year

Silence Therapeutics plc (SLN) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
Today15.0×—$19.80—
20254.6× 94.1% up$6.08$1.32
20242.4× 91.9% down$6.88$2.90
202329.3× 59.4% up$17.37$0.59
202218.4×—$15.25$0.83

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

More on SLN

Silence Therapeutics plc, figure by figure

Silence Therapeutics plc (SLN) overview: price, valuation and scorecard

Silence Therapeutics plc P/B ratio: questions and answers

What is Silence Therapeutics plc's P/B ratio?

Silence Therapeutics plc (SLN) trades at 15.0× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 4.6×. That is 94.1% higher than the 2.4× of fiscal 2024.

Is Silence Therapeutics plc's P/B ratio high or low compared with its own history?

Today's P/B ratio is higher than at 50% of the 4 fiscal year-ends on record; their median is 11.5×.

What are the highest and lowest P/B ratio figures on record for Silence Therapeutics plc?

Across the 4 fiscal year-ends on record (2022–2025), the highest was 29.3× in fiscal 2023 and the lowest 2.4× in fiscal 2024.

How is Silence Therapeutics plc's P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Silence Therapeutics plc it is on record here for 4 fiscal years, 2022 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Silence Therapeutics plc (SLN) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/SLN/pb-ratio

Underlying data: Yahoo Finance.